Overview

Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 4 weeks in the treatment of hypogonadal men with chronic obstructive pulmonary disease (COPD) that are on oral glucocorticoid therapy.

Phase:

Phase 2

Details

Lead Sponsor:

QuatRx Pharmaceuticals Company

Treatments:

Glucocorticoids
Tamoxifen